Presynaptic APP levels and synaptic homeostasis are regulated by Akt phosphorylation of Huntingtin

Abstract

Studies have suggested that amyloid precursor protein (APP) regulates synaptic homeostasis, but the evidence has not been consistent. In particular, signaling pathways controlling APP transport to the synapse in axons and dendrites remain to be identified. Having previously shown that Huntingtin (HTT), the scaffolding protein involved in Huntington's disease, regulates neuritic transport of APP, we used a microfluidic corticocortical neuronal network-on-a-chip to examine APP transport and localization to the pre- and post-synaptic compartments. We found that HTT, upon phosphorylation by the Ser/Thr kinase Akt, regulates APP transport in axons but not dendrites. Expression of an unphosphorylatable HTT decreased axonal anterograde transport of APP, reduced presynaptic APP levels, and increased synaptic density. Ablating in vivo HTT phosphorylation in APPPS1 mice, which overexpress APP, reduced presynaptic APP levels, restored synapse number and improved learning and memory. The Akt-HTT pathway and axonal transport of APP thus regulate APP presynaptic levels and synapse homeostasis.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Julie Bruyère

    INSERM U1216, Grenoble Institut Neurosciences, University Grenoble Alpes, Grenoble, France
    Competing interests
    No competing interests declared.
  2. Yah-Se Abada

    Institut du Cerveau et de la Moelle épinière, ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Université, Paris, France
    Competing interests
    No competing interests declared.
  3. Hélène Marine Vitet

    INSERM U1216, Grenoble Institut Neurosciences, University Grenoble Alpes, Grenoble, France
    Competing interests
    No competing interests declared.
  4. Gaëlle Fontaine

    Institut du Cerveau et de la Moelle épinière, ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Université, Paris, France
    Competing interests
    No competing interests declared.
  5. Jean-Christophe Deloulme

    Inserm U 1216 Grenoble Institut Neurosciences, University Grenoble Alpes, Grenoble, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2234-5865
  6. Aurélia Cès

    Institut du Cerveau et de la Moelle épinière, ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Université, Paris, France
    Competing interests
    No competing interests declared.
  7. Eric Denarier

    Inserm U 1216 Grenoble Institut Neurosciences, University Grenoble Alpes, Grenoble, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4169-397X
  8. Karin Pernet-Gallay

    INSERM U1216, Grenoble Institut Neurosciences, University Grenoble Alpes, Grenoble, France
    Competing interests
    No competing interests declared.
  9. Annie Andrieux

    Inserm U1216, CEA, Grenoble Institut Neurosciences, University Grenoble Alpes, Grenoble, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4022-6405
  10. Sandrine Humbert

    INSERM U1216, Grenoble Institut Neurosciences, University Grenoble Alpes, Grenoble, France
    Competing interests
    No competing interests declared.
  11. Marie-Claude Potier

    Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMRS 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France
    Competing interests
    No competing interests declared.
  12. Benoît Delatour

    Institut du Cerveau et de la Moelle épinière, ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Université, Paris, France
    Competing interests
    No competing interests declared.
  13. Frédéric Saudou

    INSERM U1216, Grenoble Institut Neurosciences, University Grenoble Alpes, Grenoble, France
    For correspondence
    frederic.saudou@inserm.fr
    Competing interests
    Frédéric Saudou, is on the scientific advisory board of Servier (Neurosciences Department) and a consultant for TEVA and Wave Life Sciences. The other authors declare that they have no competing interests..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6107-1046

Funding

Agence Nationale de la Recherche (ANR-12-MALZ-0004 HuntAbeta)

  • Frédéric Saudou

Agence Nationale de la Recherche (ANR-15-IDEX-02 NeuroCoG)

  • Frédéric Saudou

Agence Nationale de la Recherche (ANR-10-IAIHU-06)

  • Marie-Claude Potier

Fondation pour la Recherche Médicale (DEQ20170336752)

  • Sandrine Humbert

Fondation pour la Recherche Médicale (FDT201904008035)

  • Hélène Marine Vitet

Fondation pour la Recherche Médicale (DEI20151234418)

  • Frédéric Saudou

Fondation pour la Recherche sur le Cerveau

  • Frédéric Saudou

INSERM (AGEMED)

  • Frédéric Saudou

Fondation Bettencourt Schueller

  • Frédéric Saudou

Association Huntington France

  • Hélène Marine Vitet

Agence Nationale de la Recherche (ANR-12-MALZ-0004 HuntAbeta)

  • Marie-Claude Potier

INSERM (AGEMED)

  • Sandrine Humbert

Agence Nationale de la Recherche (ANR-14-CE35-0027-01 PASSAGE)

  • Frédéric Saudou

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animals were held in accordance with the French Animal Welfare Act and the EU legislation (Council Directive 86/609/EEC) and the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. The French Ministry of Agriculture and the local ethics committee gave specific authorization (authorization no. 04594.02) to BD to conduct the experiments described in the present study.

Copyright

© 2020, Bruyère et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,153
    views
  • 349
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Julie Bruyère
  2. Yah-Se Abada
  3. Hélène Marine Vitet
  4. Gaëlle Fontaine
  5. Jean-Christophe Deloulme
  6. Aurélia Cès
  7. Eric Denarier
  8. Karin Pernet-Gallay
  9. Annie Andrieux
  10. Sandrine Humbert
  11. Marie-Claude Potier
  12. Benoît Delatour
  13. Frédéric Saudou
(2020)
Presynaptic APP levels and synaptic homeostasis are regulated by Akt phosphorylation of Huntingtin
eLife 9:e56371.
https://doi.org/10.7554/eLife.56371

Share this article

https://doi.org/10.7554/eLife.56371

Further reading

    1. Cell Biology
    Satoshi Ninagawa, Masaki Matsuo ... Kazutoshi Mori
    Research Advance

    How the fate (folding versus degradation) of glycoproteins is determined in the endoplasmic reticulum (ER) is an intriguing question. Monoglucosylated glycoproteins are recognized by lectin chaperones to facilitate their folding, whereas glycoproteins exposing well-trimmed mannoses are subjected to glycoprotein ER-associated degradation (gpERAD); we have elucidated how mannoses are sequentially trimmed by EDEM family members (George et al., 2020; 2021 eLife). Although reglucosylation by UGGT was previously reported to have no effect on substrate degradation, here we directly tested this notion using cells with genetically disrupted UGGT1/2. Strikingly, the results showed that UGGT1 delayed the degradation of misfolded substrates and unstable glycoproteins including ATF6α. An experiment with a point mutant of UGGT1 indicated that the glucosylation activity of UGGT1 was required for the inhibition of early glycoprotein degradation. These and overexpression-based competition experiments suggested that the fate of glycoproteins is determined by a tug-of-war between structure formation by UGGT1 and degradation by EDEMs. We further demonstrated the physiological importance of UGGT1, since ATF6α cannot function properly without UGGT1. Thus, our work strongly suggests that UGGT1 is a central factor in ER protein quality control via the regulation of both glycoprotein folding and degradation.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Senem Ntourmas, Martin Sachs ... Dominic B Bernkopf
    Research Article

    Activation of the Wnt/β-catenin pathway crucially depends on the polymerization of dishevelled 2 (DVL2) into biomolecular condensates. However, given the low affinity of known DVL2 self-interaction sites and its low cellular concentration, it is unclear how polymers can form. Here, we detect oligomeric DVL2 complexes at endogenous protein levels in human cell lines, using a biochemical ultracentrifugation assay. We identify a low-complexity region (LCR4) in the C-terminus whose deletion and fusion decreased and increased the complexes, respectively. Notably, LCR4-induced complexes correlated with the formation of microscopically visible multimeric condensates. Adjacent to LCR4, we mapped a conserved domain (CD2) promoting condensates only. Molecularly, LCR4 and CD2 mediated DVL2 self-interaction via aggregating residues and phenylalanine stickers, respectively. Point mutations inactivating these interaction sites impaired Wnt pathway activation by DVL2. Our study discovers DVL2 complexes with functional importance for Wnt/β-catenin signaling. Moreover, we provide evidence that DVL2 condensates form in two steps by pre-oligomerization via high-affinity interaction sites, such as LCR4, and subsequent condensation via low-affinity interaction sites, such as CD2.